{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:40:46Z","timestamp":1760834446592,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jocn.2020.03.047","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T01:00:41Z","timestamp":1586394041000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A review of possible therapies for Parkinson\u2019s disease"],"prefix":"10.1016","volume":"76","author":[{"given":"Ashok","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jocn.2020.03.047_b0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues Clin Neurosci"},{"issue":"40","key":"10.1016\/j.jocn.2020.03.047_b0010","first-page":"1","article-title":"Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s disease","volume":"23","author":"Haddad","year":"2018","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jocn.2020.03.047_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03033137","article-title":"Dopamine or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease","volume":"5","author":"Asanuma","year":"2003","journal-title":"Neurotoxicol Res"},{"key":"10.1016\/j.jocn.2020.03.047_b0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fnins.2018.00693","article-title":"Emerging treatment approaches for Parkinson\u2019s disease","volume":"12","author":"Stoker","year":"2018","journal-title":"Front Neurosci"},{"issue":"Suppl. 2","key":"10.1016\/j.jocn.2020.03.047_b0025","first-page":"S32","article-title":"Problems with long-term levodopa therapy for Parkinson's disease","volume":"17","author":"Marsden","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jocn.2020.03.047_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2047-9158-2-19","article-title":"Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson\u2019s disease","volume":"2","author":"Teo","year":"2013","journal-title":"Transl Neurodegener"},{"issue":"S2","key":"10.1016\/j.jocn.2020.03.047_b0035","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1017\/S031716710000007X","article-title":"COMT inhibitors in Pakinson\u2019s disease","volume":"26","author":"Rivest","year":"1999","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jocn.2020.03.047_b0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fneur.2017.00702","article-title":"A meta-analysis of adenosine A2A receptor antagonists on Levodopa-induced dyskinesia in vivo","volume":"8","author":"Wang","year":"2017","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.jocn.2020.03.047_b0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep brain stimulation for Parkinson\u2019s disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jocn.2020.03.047_b0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor complications","volume":"368","author":"Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jocn.2020.03.047_b0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.parkreldis.2013.07.021","article-title":"Timmermann L Multiple source current steering\u2013a novel deep brain stimulation concept for customized programming in a Parkinson\u2019s disease patient","volume":"20","author":"Barbe","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2020.03.047_b0060","series-title":"134 vantage trial: three-year outcomes of a prospective, multicenter trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson disease","first-page":"155","author":"Timmermann","year":"2016"},{"issue":"Suppl 1","key":"10.1016\/j.jocn.2020.03.047_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jnc.13649","article-title":"Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation","volume":"139","author":"McIntyre","year":"2016","journal-title":"J Neurochem"},{"issue":"23","key":"10.1016\/j.jocn.2020.03.047_b0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tins.2011.01.003","article-title":"(2011) Rewiring the brain with cell transplantation in Parkinson\u2019s disease","volume":"34","author":"Gaillard","year":"2011","journal-title":"Trends Neurosci"},{"issue":"6","key":"10.1016\/j.jocn.2020.03.047_b0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.celrep.2012.04.009","article-title":"Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions","volume":"1","author":"Kirkeby","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.jocn.2020.03.047_b0080","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/ncomms6627","article-title":"Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF","volume":"5","author":"Yang","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jocn.2020.03.047_b0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.brainresbull.2006.07.001","article-title":"Induction of dopaminergic neurons from growth factor expanded neural stem\/progenitor cell cultures derived from human first trimester forebrain","volume":"70","author":"Christophersen","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jocn.2020.03.047_b0090","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/stem.37","article-title":"Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine","volume":"27","author":"Knoepfler","year":"2009","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.jocn.2020.03.047_b0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.32607\/20758251-2010-2-2-18-27","article-title":"Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine","volume":"2","author":"Medvedev","year":"2010","journal-title":"Acta Nat"},{"key":"10.1016\/j.jocn.2020.03.047_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138460","article-title":"Noggin over-expressing mouse embryonic fibroblasts and ms5 stromal cells enhance directed differentiation of dopaminergic neurons from human embryonic stem cells","volume":"10","author":"Lim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2020.03.047_b0105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1096\/fj.06-6649rev","article-title":"Human skin pigmentation: melanocytes modulate skin color in response to stress","volume":"21","author":"Costin","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.jocn.2020.03.047_b0110","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1523\/JNEUROSCI.19-09-03519.1999","article-title":"Catecholamine synthesis is mediated by tyrosinase in the absence of tyrosine hydroxylase","volume":"19","author":"Rios","year":"1999","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.jocn.2020.03.047_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065983","article-title":"Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-Parkinsonian models","volume":"8","author":"Asanuma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2020.03.047_b0120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.4103\/1673-5374.197124","article-title":"Two-step production of monoamines in monoenzymatic cells in the spinal cord: a different control strategy of neurotransmitter supply?","volume":"11","author":"Zhang","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.jocn.2020.03.047_b0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuroscience.2015.04.021","article-title":"Striatal tyrosine hydroxylase-positive neurons are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"298","author":"Keber","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.jocn.2020.03.047_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","article-title":"Tyrosine hydroxylase and regulation of dopamine synthesis","volume":"508","author":"Colette Daubner","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jocn.2020.03.047_b0135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"6645","key":"10.1016\/j.jocn.2020.03.047_b0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"5321","key":"10.1016\/j.jocn.2020.03.047_b0145","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.jocn.2020.03.047_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.jocn.2020.03.047_b0155","first-page":"67","article-title":"Genetic basis of Parkinson\u2019s disease: inheritance, penetrance, and expression","volume":"4","author":"Schulte","year":"2011","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.jocn.2020.03.047_b0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2008.06.007","article-title":"Decreased NURR1 gene expression in patients with Parkinson\u2019s disease","volume":"273","author":"Le","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2020.03.047_b0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.15252\/emmm.201506162","article-title":"Combined Nurr1 and Foxa2 roles in the therapy of Parkinson\u2019s disease","volume":"8","author":"Oh","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jocn.2020.03.047_b0170","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cns.12536","article-title":"Nurr1-based therapies for Parkinson\u2019s disease","volume":"22","author":"Dong","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jocn.2020.03.047_b0175","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2020.03.047_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pmic.201600092","article-title":"Leucine-rich repeat kinase 2 and Parkinson\u2019s disease","volume":"17","author":"Kang","year":"2017","journal-title":"Proteomics"},{"key":"10.1016\/j.jocn.2020.03.047_b0185","doi-asserted-by":"crossref","first-page":"18283","DOI":"10.1074\/jbc.M115.703157","article-title":"Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces alpha-synuclein aggregation","volume":"291","author":"Follett","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jocn.2020.03.047_b0190","doi-asserted-by":"crossref","first-page":"40135","DOI":"10.1074\/jbc.M505036200","article-title":"The DnaJ-domain protein RME-8 functions in endosomal trafficking","volume":"280","author":"Girard","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jocn.2020.03.047_b0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.26064","article-title":"DNAJC13 genetic variants in parkinsonism","volume":"30","author":"Gustavsson","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2020.03.047_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","article-title":"Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism","volume":"5","author":"Schrag","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2020.03.047_b0205","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","article-title":"Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene","volume":"342","author":"Lucking","year":"2000","journal-title":"N Engl J Med"},{"year":"2017","series-title":"Leucine-rich repeat kinase 2 and Parkinson\u2019s disease. Proteomics 17. The recently developed \u201cclustered regularly interspaced short palindromic repeats\u201d technology (CRISPR) in conjunction with the endonuclease CAS9","author":"Kang","key":"10.1016\/j.jocn.2020.03.047_b0210"},{"key":"10.1016\/j.jocn.2020.03.047_b0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/522020a","article-title":"CRISPR, the disruptor","volume":"522","author":"Ledford","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jocn.2020.03.047_b0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.jocn.2020.03.047_b0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","article-title":"Active immunization therapies for Parkinson's disease and multiple system atrophy","volume":"31","author":"Schneeberger","year":"2016","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.jocn.2020.03.047_b0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamaneurol.2018.0346","article-title":"Challenges in passive immunization strategies to treat Parkinson disease","volume":"75","author":"Manfredsson","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.jocn.2020.03.047_b0235","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.26731","article-title":"The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations","volume":"31","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2016","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.jocn.2020.03.047_b0240","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/mds.26728","article-title":"The best medicine? The influence of physical activity and inactivity on Parkinson\u2019s disease","volume":"31","author":"LaHue","year":"2016","journal-title":"Mov Disord"},{"issue":"22","key":"10.1016\/j.jocn.2020.03.047_b0245","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0000000000003989","article-title":"Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder","volume":"88","author":"Antelmi","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2020.03.047_b0250","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","article-title":"Dermal phospho-alpha-synuclein deposits confirm REM sleep behavior disorder as prodromal Parkinson's disease","volume":"133","author":"Doppler","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jocn.2020.03.047_b0255","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/mds.27094","article-title":"FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder","volume":"32","author":"Meles","year":"2017","journal-title":"Mov Disord"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820301375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820301375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:21:46Z","timestamp":1760822506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586820301375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":51,"alternative-id":["S0967586820301375"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2020.03.047","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of possible therapies for Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2020.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}